



Poly (I:C) PR8 Poly (I:C) 0 1 2 3 (μg) (μg) (μg) (μg) (μg) (10 1 10 10 10 10 10 10 10 10 10 10 10 1
, H
VVV
1
1 ** * * * * * * * * * * * * * * * * *
ation 1
ation 1
ation 1

*: p < 0.01




Note: Vaccine alone for secondary immunization




Note: Vaccine alone for secondary immunization


*: p < 0.01


FIG. 5





	Anti-HA serum-IqG (4^n)	10000000000000000000000000000000000000			6 ≤ 1 2 3 4 5 6 7 8	Anti-NA serum-IgG (4^n)				6 ≤1 2 3 4 5 6 7 8
4 H - i + 4 G	NW-IGA (2 ⁿ)			T	-50	$NW-IgA$ (2^n)				2 3 4 5 6
vac	. FOLY 1:C	+ 0.1(#)	+ 0.1(H)	+ 0.1(L)	VII		+ 0.1(M)	+ 0.1(H)	+ 0.1(L)	Ŭ.
Secon	(hg)	0.4	0.4	0.4			0.4	0.4	0.4	
Primary vaccine (0w)	((bd)	+ 0.1(M)	+ 0.1(H)	+ 0.1(L)			+ 0.1(H)	.+ 0.1(H)	+ 0.1(L)	
Primary v NC vaccin	(hg))	0.4	0.4	0.4			0.4	0.4	0.4	





*(); * (); Interval between primary vaccination and secondary vaccination

